AOD9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Film and television === In the Adventure Time television series, the main antagonist is an evil, powerful undead being known simply as "The Lich". He describes himself as an ancient, cosmic being who is the manifestation of the inevitable death of all things.
Parenteral nutrition (PN), or intravenous feeding, is the feeding of nutritional products to a person intravenously, bypassing the usual process of eating and digestion. The products are made by pharmaceutical compounding entities or standard pharmaceutical companies. The person receives a nutritional mix according to a formula including glucose, salts, amino acids, lipids, vitamins, and dietary minerals. It is called total parenteral nutrition (TPN) or total nutrient admixture (TNA) when no significant nutrition is obtained by other routes, and partial parenteral nutrition (PPN) when nutrition is also partially enteric. It is called peripheral parenteral nutrition (PPN) when administered through vein access in a limb rather than through a central vein as in central venous nutrition (CVN).
The average gross monthly wage in Moscow is ₽123,688 ($2,000); this wage is around twice the national average of ₽66,572 ($1,000), and it is one of the highest among the federal subjects (constituent entities) of Russia. Moscow is home to the third-highest number of billionaires among cities internationally, and the highest number among cities in Europe. Moscow is Russia's financial center, as well as headquarters for the country's largest banks and many of its largest companies (e.g., energy company Rosneft). Moscow accounts for 17% of Russia's retail sales and 13% of its construction activity. Since the 1998 Russian financial crisis, business sectors in Moscow have shown strong growth. Many business centers and office buildings have been constructed in recent years, but Moscow still has a shortage of office space. As a result, many former industrial and research facilities are being rebuilt for office use. Economic stability has improved overall in recent years; nonetheless, crime and corruption hinder business development.
== Structure == Human and yeast glutathione synthetases are homodimers, meaning they are composed of two identical subunits of itself non-covalently bound to each other. On the other hand, E. coli glutathione synthetase is a homotetramer. Nevertheless, they are part of the ATP-grasp superfamily, which consists of 21 enzymes that contain an ATP-grasp fold. Each subunit interacts with each other through alpha helix and beta sheet hydrogen bonding interactions and contains two domains. One domain facilitates the ATP-grasp mechanism and the other is the catalytic active site for γ-glutamylcysteine. The ATP-grasp fold is conserved within the ATP-grasp superfamily and is characterized by two alpha helices and beta sheets that hold onto the ATP molecule between them. The domain containing the active site exhibits interesting properties of specificity. In contrast to γ-glutamylcysteine synthetase, glutathione synthetase accepts a large variety of glutamyl-modified analogs of γ-glutamylcysteine, but is much more specific for cysteine-modified analogs of γ-glutamylcysteine. Crystalline structures have shown glutathione synthetase bound to GSH, ADP, two magnesium ions, and a sulfate ion. Two magnesium ions function to stabilize the acylphosphate intermediate, facilitate binding of ATP, and activate removal of phosphate group from ATP. Sulfate ion serves as a replacement for inorganic phosphate once the acylphosphate intermediate is formed inside the active site.
==== MeSH E05.200.750 – histological techniques ==== MeSH E05.200.750.132 – autoradiography MeSH E05.200.750.210 – bone demineralization technique MeSH E05.200.750.288 – decalcification technique MeSH E05.200.750.551 – histocytochemistry MeSH E05.200.750.551.512 – immunohistochemistry MeSH E05.200.750.551.512.240 – fluorescent antibody technique MeSH E05.200.750.551.512.240.300 – fluorescent antibody technique, direct MeSH E05.200.750.551.512.240.310 – fluorescent antibody technique, indirect MeSH E05.200.750.551.790 – periodic acid-schiff reaction MeSH E05.200.750.551.810 – prussian blue reaction MeSH E05.200.750.600 – histocytological preparation techniques MeSH E05.200.750.600.520 – microdissection MeSH E05.200.750.600.530 – microtomy MeSH E05.200.750.600.530.160 – cryoultramicrotomy MeSH E05.200.750.600.530.160.260 – frozen sections MeSH E05.200.750.600.620 – replica techniques MeSH E05.200.750.600.620.150 – corrosion casting MeSH E05.200.750.600.620.260 – freeze fracturing MeSH E05.200.750.600.620.260.400 – freeze etching MeSH E05.200.750.600.670 – staining and labeling MeSH E05.200.750.600.670.130 – chromosome banding MeSH E05.200.750.600.670.325 – in situ hybridization MeSH E05.200.750.600.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.750.600.670.325.350.125 – chromosome painting MeSH E05.200.750.600.670.325.680 – primed in situ labeling MeSH E05.200.750.600.670.520 – negative staining MeSH E05.200.750.600.670.620 – periodic acid-schiff reaction MeSH E05.200.750.600.670.660 – prussian blue reaction MeSH E05.200.750.600.670.770 – shadowing (histology) MeSH E05.200.750.600.670.780 – silver staining MeSH E05.200.750.600.720 – tissue embedding MeSH E05.200.750.600.720.610 – paraffin embedding MeSH E05.200.750.600.720.640 – plastic embedding MeSH E05.200.750.600.760 – tissue preservation MeSH E05.200.750.600.760.160 – cryopreservation MeSH E05.200.750.600.760.160.260 – freeze drying MeSH E05.200.750.600.760.160.260.270 – freeze substitution MeSH E05.200.750.600.760.720 – tissue fixation
Sources: en.wikipedia.org
Brazil: The leaf juice is taken orally to induce vomiting and narcosis. Colombia: Fresh leaf is used as poultice over boils and infected wounds; the leaves are crushed with oil from palms and used as hair treatment to prevent baldness. Cuba: Extract of the leaf is taken orally to treat dysmenorrhea. East Africa: Dried leaves of Nicotiana tabacum and Securinega virosa are mixed into a paste and used externally to destroy worms in sores. Ecuador: Leaf juice is used for indisposition, chills and snake bites and to treat pulmonary ailments. Fiji: Fresh root is taken orally for asthma and indigestion; fresh root is applied ophthalmically as drops for bloodshot eyes and other problems; seed is taken orally for rheumatism and to treat hoarseness. Guatemala: Leaves are applied externally by adults for myiasis, headache and wounds; hot water extract of the dried leaf is applied externally for ring worms, fungal diseases of the n, wounds, ulcers, bruises, sores, mouth lesions, stomatitis and mucosa; leaf is orally taken for kidney diseases. Haiti: Decoction of dried leaf is taken orally for bronchitis and pneumonia. Hong Kong: Fresh leaves are mashed and combined with vegetable oil to create a potion that is applied to injuries for it to heal faster. This practice is also apparent in other places in China. Iran: Infusion of the dried leaf is applied externally as an insect repellent; ointments made from crushed leaves are used for baldness, dermatitis and infectious ulceration and as a pediculicide.
. These are the number of people in the susceptible, infected and removed categories at time equals zero. If the SIR model is assumed to hold at all times, these initial conditions are not independent. Subsequently, the flow model updates the three variables for every time point with set values for
==== Dust-transfer technique ==== The scientists Emily Craig and Randall Bresee have attempted to recreate the likenesses of the shroud through the dust-transfer technique, which could have been done by medieval arts. They first did a carbon-dust drawing of a Jesus-like face (using collagen dust) on a newsprint made from wood pulp (which is similar to 13th- and 14th-century paper). They next placed the drawing on a table and covered it with a piece of linen. They then pressed the linen against the newsprint by firmly rubbing with the flat side of a wooden spoon. By doing this they managed to create a reddish-brown image with a lifelike positive likeness of a person, a three-dimensional image and no sign of brush strokes.
== Operations == Dutch Bros is headquartered in Tempe, Arizona. It had been based in Grants Pass, Oregon, since its 1992 founding, but began moving some corporate offices to Arizona in early 2024 and in June 2025 announced that it was relocating its headquarters there. The company is majority-owned by Travis Boersma, who holds the title of executive chairman, and Christine Barone is its president and CEO. In September 2021, Dutch Bros became a publicly traded company, selling 21 million shares for a total of $484 million. As of December 2023, the company employed approximately 24,000 people, and as of August 2024, it had 912 stores. In 2024, Dutch Bros opened a distribution and roasting center in Melissa, Texas. The center is a 65,000-square-foot plant located at the intersection of U.S. 75 and State Highway 121. In January 2026, it was announced that Dutch Bros had agreed to acquire Clutch Coffee Bar, a regional drive-through coffee chain with 20 locations across North and South Carolina. The financial terms were not disclosed, and Dutch Bros stated that the acquired locations would be closed, renovated, and reopened under its own brand. On August 5, 2026, the company announced it would be acquiring 65 locations from the chain Salad and Go (which permanently closed all its locations the same day) across Arizona, Nevada, Oklahoma and Texas.
==== Inflammatory bowel disease (IBD)/cystitis ==== Despite strong preclinical rationale, efforts to demonstrate efficacy of SP antagonists in inflammatory disease have been unproductive. A study in women with IBS confirmed that an NK1RAs antagonist was anxiolytic.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.